Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.62 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.62 |
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 8/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 5/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12632147 | 0.80 | KIF11 (0.50) | DYRK1ADYRK1BKIF11CYP3A4CYP1A2 | |
| SCHEMBL12529424 | 0.78 | HDAC6 (0.43) | DYRK1ADYRK1BKIF11CYP2A6ALDH1A1 | |
| SCHEMBL26781848 | 0.78 | CYP2A6 (0.36) | DYRK1ADYRK1BCYP2A6 | |
| SCHEMBL14817175 | 0.77 | DYRK1A (0.68) | DYRK1ADYRK1BDYRK2CYP2A6CYP3A4 | |
| SCHEMBL26781853 | 0.76 | HSD17B1 (0.41) | KIF11CYP2A6CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL7933423 | 0.74 | DYRK1A (0.68) | DYRK1ADYRK1BDYRK2CYP2A6CYP3A4 | |
| SCHEMBL7213603 | 0.74 | DYRK1A (0.68) | DYRK1ADYRK1BDYRK2CYP2A6CYP3A4 | |
| SCHEMBL12632133 | 0.74 | CYP2A6 (0.58) | DYRK1ADYRK1BKIF11CYP2A6CYP3A4 | |
| SCHEMBL17540830 | 0.73 | DYRK1A (0.62) | DYRK1ADYRK1BKIF11DYRK2CYP2A6 | |
| SCHEMBL12531203 | 0.73 | DYRK1A (0.62) | DYRK1ADYRK1BDYRK2CYP2A6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404689-B2 | Heterocyclic amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110160207-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-30 | — | — | US | disclosed |
| US-7947684-B2 | anticoagulants; immunomoderators; antiinflammatory agents | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7935696-B2 | e.g. 5-(4-Chlorophenyl)-N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)furan-2-carboxamide; p38 alpha and beta kinase inhibitor; antiinflammatory agent; asthma, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, multiple myeloma, pain, myocardial ischemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935696-B2 | e.g. 5-(4-Chlorophenyl)-N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)furan-2-carboxamide; p38 alpha and beta kinase inhibitor; antiinflammatory agent; asthma, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, multiple myeloma, pain, myocardial ischemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080171741-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-17 | — | — | US | disclosed |
| US-20080171741-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171741-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K1, MAP3K8, MAP3K20 | DYRK1A 670/4885DYRK1B 698/4885KIF11 1831/4885 |
| US-20110160207-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K1, MAP3K8, MAP3K20 | DYRK1A 670/4885DYRK1B 698/4885KIF11 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.